Point72 Bet $1.1B on a Single Biotech While Soros Built a $10.9B Healthcare Empire: How 7 Whale Funds Played the Sector in Q4 2025

While the Q4 2025 filing season has been dominated by AI semiconductor trades and mega-cap tech rotations, a quieter but potentially more consequential shift was happening in healthcare. Across seven of the most prominent whale funds, we found over $28 billion in combined healthcare exposure — and the approaches couldn't be more different.

Point72 concentrated 11.3% of its portfolio in healthcare, anchored by a $1.1 billion bet on a single clinical-stage biotech. Soros Fund Management spread $10.9 billion across 37 healthcare positions. D.E. Shaw deployed $10.9 billion across 31 names. But the stocks they chose — and the conviction levels behind them — reveal fundamentally different views on where healthcare is headed.

TL;DR

• Total healthcare exposure: $28B+ across 7 whale funds in Q4 2025
• Highest concentration: Point72 at 11.3% of portfolio ($4.3B, 13 positions)
• Largest dollar allocation: D.E. Shaw and Soros tied at ~$10.9B each
• Consensus picks: BSX held by 4 of 7 funds; UNH, LLY, MRK each held by 3+
• Biggest single bet: Point72's BridgeBio Pharma at $1.1B (2.92% of portfolio)
• GLP-1 exposure: LLY held by Soros ($1.26B), DE Shaw ($545M); NVO held by Soros ($379M)
• Managed care: CNC favored by DE Shaw ($1.31B) and Soros ($412M); UNH preferred by Soros ($1.25B) and Point72 ($395M)
• Divergence: Point72 bets on biotech catalysts; Soros/DE Shaw prefer diversified large-cap healthcare; Lone Pine targets hospital operators

The Healthcare Allocation Leaderboard

Not all whale funds play healthcare the same way — or at all. Coatue and Pershing Square had zero healthcare exposure in Q4 2025. But for the funds that did allocate, the numbers are significant:

The standout is Point72. Steve Cohen's $37.7B multi-strategy fund allocated 11.3% to healthcare — more than double the next-highest concentration. This isn't a passive sector allocation; it's a deliberate overweight driven by specific catalyst-driven bets (more on that below).

D.E. Shaw and Soros deployed nearly identical dollar amounts (~$10.9B each), but their total AUM differs dramatically ($191B vs $182B), so the percentage weights are similar at 5.7% and 6.0% respectively. This suggests a broad institutional consensus that healthcare deserves a mid-single-digit allocation — but the stock selection diverges sharply.

The Consensus Stocks: Where Multiple Whale Funds Agree

When several billion-dollar funds independently land on the same stock, it's worth paying attention. Here are the healthcare names held by 3 or more of the 7 whale funds we analyzed:

Boston Scientific (BSX) — The Broadest Consensus

BSX appears in 4 of 7 portfolios: Soros ($1.07B), Point72 ($239M), Lone Pine ($19M), and Bridgewater ($23M via smaller positions). The med-tech giant has been a consistent outperformer, driven by its structural heart franchise (WATCHMAN) and electrophysiology platform. At a combined $1.35B+ across these funds, it's the single most widely-held healthcare name among whale funds.

UnitedHealth Group (UNH) — The Defensive Anchor

UNH is held by Soros ($1.25B), Point72 ($395M), DE Shaw ($237M), Appaloosa ($66M), and Bridgewater ($37M) — 5 funds, though at very different conviction levels. The stock has been under pressure following CEO succession questions and DOJ antitrust scrutiny, but its Optum healthcare services division provides earnings diversification that few competitors match. Soros's $1.25B position (0.69% of portfolio) suggests he views the selloff as overdone.

Eli Lilly (LLY) — The GLP-1 Battleground

LLY is held by Soros ($1.26B), DE Shaw ($545M), and Bridgewater ($79M). This is a pure bet on the GLP-1 drug revolution — Lilly's Mounjaro and Zepbound generated over $20 billion in 2025 revenue, and the obesity/diabetes market is projected to exceed $100 billion annually by 2030. Soros's $1.26B position makes LLY his largest healthcare holding. DE Shaw's $545M stake ranks it among their top-5 healthcare names.

Notably, Soros also holds Novo Nordisk (NVO) at $379M — giving him exposure to both sides of the GLP-1 duopoly. No other whale fund holds both LLY and NVO, making Soros the most committed GLP-1 investor among the group.

Merck (MRK) — The Value Play

MRK is held by DE Shaw ($1.18B), Soros ($519M), and Bridgewater ($33M). Merck has underperformed in 2025 amid Keytruda patent cliff concerns (the blockbuster cancer immunotherapy loses exclusivity in 2028). But at 10-11x forward earnings, it's among the cheapest large-cap pharma names. DE Shaw's $1.18B position — the second-largest healthcare holding in their portfolio — suggests the quant fund sees value in the depressed multiple.

Point72's Biotech Gambit: $1.1B on BridgeBio

The most aggressive healthcare positioning belongs to Point72. Steve Cohen's fund put $1.1 billion into BridgeBio Pharma (BBIO) — a single clinical-stage biotech that represents 2.92% of the entire $37.7B portfolio.

BridgeBio's lead asset, acoramidis, received FDA approval for transthyretin amyloid cardiomyopathy (ATTR-CM) in late 2024, putting it in direct competition with Pfizer's Vyndaqel franchise. The market for ATTR-CM treatments is estimated at $10B+ annually, and BridgeBio's drug showed superior efficacy in clinical trials.

Point72's other healthcare bets reinforce the biotech-catalyst theme:

• Adaptive Biotechnologies (ADPT): $487M (1.29%) — immune medicine diagnostics
• HCA Healthcare: $466M (1.24%) — the largest for-profit hospital operator
• Thermo Fisher Scientific (TMO): $460M (1.22%) — life sciences tools monopoly
• BioMarin (BMRN): $359M (0.95%) — rare disease specialist
• Medline (MDLN): $292M (0.78%) — medical supply distribution (also held by Lone Pine at $492M)

Point72's healthcare portfolio reads like a biotech venture fund disguised as a multi-strategy hedge fund. The $1.1B BBIO position alone is larger than many dedicated biotech funds' entire portfolios.

Soros vs. D.E. Shaw: Two $10.9B Healthcare Books, Different Philosophies

Despite deploying nearly identical dollar amounts, these two funds take very different approaches:

Soros Fund Management runs a diversified healthcare portfolio across 37 positions, with a clear preference for quality large-caps. The top 5 — LLY, UNH, BSX, ISRG, MRK — are all blue-chip names. Soros is the only fund holding both GLP-1 leaders (LLY + NVO), and his $741M Intuitive Surgical position is the largest robotic surgery bet among all whale funds we tracked. The portfolio reads like a healthcare-sector ETF curated by a macro investor — broad, liquid, and tilted toward secular growth themes.

D.E. Shaw has a quant-driven approach visible in the portfolio construction: 31 positions, with managed care insurer Centene (CNC) as the #1 holding at $1.31B. This is unusual — Centene is a Medicaid-focused managed care company that most growth-oriented funds avoid. DE Shaw also holds heavy positions in traditional pharma (MRK $1.18B, JNJ $802M, GILD $331M) that look more like value/factor bets than fundamental convictions. The fund's $463M Neurocrine Biosciences (NBIX) position adds a neuroscience biotech element that none of the other funds replicate.

The GLP-1 Map: Who's Betting on the Obesity Drug Revolution?

The GLP-1 drug class (Ozempic, Wegovy, Mounjaro, Zepbound) was arguably the biggest healthcare story of 2024-2025. Here's how whale funds positioned:

Fund	Eli Lilly (LLY)	Novo Nordisk (NVO)	Combined GLP-1
Soros	$1,261M	$379M	$1,640M
D.E. Shaw	$545M	—	$545M
Bridgewater	$79M	$14M	$93M
Point72	—	—	—
Lone Pine	—	—	—
Third Point	—	—	—

Soros is the clear GLP-1 conviction leader with $1.64 billion across both LLY and NVO. Point72, Lone Pine, and Third Point have zero direct GLP-1 exposure — a notable absence given the sector's growth trajectory. This divergence suggests either valuation concerns (LLY trades at 50x+ forward earnings) or a preference for healthcare exposure through other vectors (hospital operators, med-tech, biotech catalysts).

Hospital Operators & Healthcare Services: The Physical Economy Play

An underappreciated theme across these filings is the bid for hospital operators and healthcare services companies:

• Point72: HCA Healthcare $466M (1.24%)
• D.E. Shaw: Tenet Healthcare (THC) $448M (0.24%)
• Lone Pine: Tenet Healthcare $355M (2.61%) + Medline $492M (3.62%)
• Soros: Tenet Healthcare $236M (0.13%)

Three funds hold Tenet Healthcare (THC) — the for-profit hospital operator that has been aggressively consolidating and improving margins. Combined with HCA exposure, the whale fund community has a clear view that hospital consolidation is creating pricing power, and that the aging US population plus Medicaid expansion are structural demand tailwinds.

Medline, the recently-IPO'd medical supply distributor, shows up in both Point72 ($292M) and Lone Pine ($492M) — a combined $784M bet on healthcare logistics that is entirely absent from the other five funds.

What's Missing: Healthcare Stocks the Whale Funds Avoided

Absences can be as informative as holdings:

• Pfizer (PFE): Only held by Soros ($333M) and DE Shaw ($245M) at small weights — the post-COVID hangover continues
• AbbVie (ABBV): Only DE Shaw ($263M) and Soros ($263M) — Humira biosimilar competition weighing on conviction
• Amgen (AMGN): Not a top holding for any of the 7 funds despite being the 5th-largest biotech by market cap
• Moderna (MRNA): Completely absent from all 7 portfolios — the mRNA platform thesis has clearly lost institutional support

Frequently Asked Questions

Which whale fund has the most healthcare exposure in Q4 2025?

By concentration, Point72 leads at 11.3% of portfolio ($4.3B across 13 positions). By dollar amount, D.E. Shaw and Soros are tied at approximately $10.9B each.

What is the most widely held healthcare stock among hedge funds?

Boston Scientific (BSX) appears in 4 of 7 whale fund portfolios, with a combined value exceeding $1.35B. UnitedHealth Group (UNH) is held by 5 funds but at lower total conviction.

Are hedge funds buying GLP-1 stocks like Eli Lilly?

Selectively. Soros is the biggest GLP-1 bull with $1.64B across LLY and NVO. D.E. Shaw holds $545M in LLY. But Point72, Lone Pine, and Third Point have zero direct GLP-1 exposure, suggesting valuation concerns at current multiples.

What is Point72's largest healthcare holding?

BridgeBio Pharma (BBIO) at $1.1 billion (2.92% of portfolio) — a concentrated bet on the acoramidis franchise competing with Pfizer's Vyndaqel in the ATTR-CM market.

Did any whale fund completely avoid healthcare in Q4 2025?

Yes. Coatue Management (95%+ tech) and Pershing Square had zero healthcare holdings in Q4 2025.

Analyst Conclusion

Healthcare in Q4 2025 is a study in divergent conviction. The funds that played it committed heavily — Point72 at 11.3%, Soros and DE Shaw each at ~$10.9B — but they chose radically different stocks. Point72 bet on biotech catalysts (BBIO, ADPT, BMRN). Soros built a diversified large-cap portfolio with GLP-1 exposure (LLY, NVO). DE Shaw ran a quant-driven approach favoring managed care (CNC) and value pharma (MRK, JNJ).

The consensus stocks — BSX, UNH, LLY, MRK, THC — tell a story of institutional preference for companies with structural competitive advantages: devices with high switching costs, managed care with government contract moats, and pharma with pipeline optionality. The absence of Moderna and the minimal Pfizer exposure suggest the post-pandemic healthcare trade is fully unwound.

For investors looking to follow the smart money into healthcare, the clearest signal is BSX (broadest consensus), LLY (highest-conviction GLP-1 play), and THC/HCA (hospital consolidation thesis). But the more interesting question may be whether Point72's $1.1B BridgeBio gambit pays off — if it does, it could be the single highest-return healthcare trade of the filing season.

Explore individual fund portfolios: Point72 | Soros Fund | D.E. Shaw | Lone Pine | Third Point. Or read our Q4 2025 institutional consensus report for the full cross-sector picture.